Beyond the Plate: Redefining the ‘Dietary Substance’
For decades, a quiet tension has existed within the dietary supplement industry regarding what actually constitutes a “dietary substance.” The traditional view often anchored ingredients to the conventional food supply, but as science evolves, this narrow interpretation is facing a reckoning.
Industry experts, including Scott Bass, a principal at Scott Bass Life Sciences LLC and one of the architects of the Dietary Supplement Health and Education Act (DSHEA), have highlighted a critical “innovation section” within the law. The debate now centers on whether a substance must have a history of being eaten to be eligible as a supplement.
The prevailing trend is a push toward a “forward-looking, catch-all innovation category.” Proponents argue that Congress always intended for DSHEA to encompass substances that aren’t necessarily common foods. For instance, compounds like co-enzyme Q10, glucosamine, and various synthesized compounds were contemplated by legislative history despite not being staples of the average diet.
The Natural Products Association (NPA) has noted that a overly restrictive “commonly used as food” test may actually discourage companies from submitting New Dietary Ingredient Notifications (NDINs), potentially pushing them toward GRAS (generally recognized as safe) self-affirmation instead.
The Lab-to-Label Pipeline: Precision Fermentation and Synthesis
We are entering an era where the way an ingredient is made is becoming as important as what the ingredient is. Emerging technologies—such as precision fermentation, cell culture, recombinant production, and chemical synthesis—are allowing manufacturers to create high-purity ingredients without relying on traditional agriculture.
The industry is now advocating for a “product- and risk-based approach.” The core argument is simple: if the final molecule is identical in structure, sequence, and safety to its traditional counterpart, the manufacturing method should not automatically trigger a new regulatory status.
According to the Council for Responsible Nutrition (CRN), these modern methods often improve purity without altering the fundamental identity of the ingredient. The future of regulatory scrutiny will likely shift away from how it was made and toward measurable characteristics, including:
- Structure and Sequence: Does the molecular blueprint remain unchanged?
- Impurity Profiles: Does the new process introduce new byproducts?
- Bioactivity: Is the bioavailability and stability consistent?
Decoding the Microbiome: The New Era of Probiotics
The science of microbials is moving far beyond simple “food-based” probiotics. The International Probiotics Association (IPA) has argued that using “food origin” as a proxy for eligibility is unscientific, given that humans are exposed to microbes through soil, plants, and other incidental sources.
The emerging trend in microbial regulation is a tiered approach to identity:
1. Species-Level Identity
Core characteristics like metabolism and physiology are generally shared at the species level. If a species has a history of safe leverage, it should qualify as a dietary substance.
2. Strain-Level Specificity
While species determine eligibility, the specific strain determines the benefit. Regulatory focus is shifting toward strain-level review for safety factors, such as antimicrobial resistance and toxigenicity.
This framework is expected to extend to “postbiotics”—non-viable microorganisms—ensuring that the next generation of gut-health products can reach the market based on rigorous scientific criteria rather than restrictive origin stories.
The Transparency Tug-of-War: Labeling Modern Ingredients
As lab-grown ingredients develop into more common, a new conflict is emerging: consumer transparency. While manufacturers seek the regulatory ease of “sameness,” some organizations are calling for clear distinctions on the label.
The American Herbal Products Association (AHPA) has suggested that the market should be informed when a compound is produced via modern techniques versus traditional agriculture. Imagine a Supplement Facts panel that distinguishes between:
- Saffron Extract (Crocus sativus) (Traditionally sourced)
- Saffrosides (from cell culture) (Modernly produced)
This trend toward “source transparency” suggests that while the FDA may accept a synthesized ingredient as “the same” for safety purposes, the marketplace may demand a different level of disclosure to maintain consumer trust.
Frequently Asked Questions
Does a dietary ingredient have to come from food to be legal?
While traditionally viewed this way, many industry experts and legislative historians argue that the “dietary substance” category is an innovation door intended to include substances not commonly found in the conventional food supply.
Does changing the production method (e.g., to precision fermentation) create a “new” ingredient?
Industry consensus is that a change in method alone should not create a new ingredient. Instead, the focus should be on whether the change materially alters the ingredient’s identity, purity, or safety profile.
How is “sameness” determined for complex ingredients like proteins?
For peptides and proteins, identity is typically determined by the amino acid sequence (or mixture profile) and the molecular weight/size distribution.
Stay Ahead of Regulatory Shifts
The landscape of dietary supplements is shifting from “tradition-based” to “science-based.” Are your products ready for the next wave of FDA scrutiny?
Join the conversation in the comments below or subscribe to our newsletter for the latest industry intelligence.
